Secor Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Secor Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4,814	Closed	-$245K	–	615
2018 Q1	$245K	Sell	4,814 -2,116	-31%	-$107K	0.02%	455
2017 Q4	$321K	Buy	+6,930	New	+$340K	0.01%	415
2015 Q1	–	Sell	-11,564	Closed	-$507K	–	523
2014 Q4	$507K	Buy	+11,564	New	+$530K	0.21%	176

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Secor Capital Advisors's RARE Position: Q2 2018 in Review

Secor Capital Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2018, closing a stake of 4,814 shares — an estimated $245K sold.

Secor Capital Advisors first reported a position in RARE in Q4 2014 and held it in 3 quarters. The position peaked at $507K in Q4 2014. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2018.

Secor Capital Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q2 2018 after selling out during the quarter.
Secor Capital Advisors sold 4,814 Ultragenyx Pharmaceutical shares in Q2 2018, an estimated $245K.
Secor Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and held it in 3 quarters.
Secor Capital Advisors's Ultragenyx Pharmaceutical position peaked at $507K in Q4 2014.
158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2018.

Based on Secor Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.